Inspire Advisors’s CytomX Therapeutics CTMX Stock Holding History

Inspire Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-75	Closed	–	–	226
2020 Q4	$0	Buy	+75	New	+$536	﹤0.01%	793

Other funds holding CTMX

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Inspire Advisors's CTMX Position: Q1 2021 in Review

Inspire Advisors sold out of CytomX Therapeutics (CTMX) in Q1 2021, closing a stake of 75 shares.

Inspire Advisors first reported a position in CTMX in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 126 funds tracked by Wall St. Rank hold CTMX as of Q1 2021.

Inspire Advisors reported no remaining CytomX Therapeutics position as of Q1 2021 after selling out during the quarter.
Inspire Advisors sold 75 CytomX Therapeutics shares in Q1 2021.
Inspire Advisors first reported a position in CytomX Therapeutics in Q4 2020 and held it in 1 quarter.
Inspire Advisors's CytomX Therapeutics position peaked at $0 in Q4 2020.
126 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2021.

Based on Inspire Advisors's 13F filing for Q1 2021, filed 30 Apr 2021.